Adjunctive recombinant IFN-γ (IMUKIN gamma-interferon-1b recombinant human 2 million IU/0.5 mL injection vial; Boehringer Ingelheim International, Ingelheim, Germany) subcutaneously at 100 mcg three times per week was administered until complete eradication of the mycobacterial infection and patient recovery. This evidence concerns the gene IFNG and mycobacterial infectious disease.